HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 41^st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 9, 2023, at 4:30 p.m. EST / 1:30 p.m. PST. HIL-214, HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.

Presentation details:
Date:	Monday, January 9, 2023
Time:	1:30 – 2:10 p.m. Pacific Standard Time (PST)
Moderator:	Eric Joseph, Ph.D.
Location:	Borgia Room, Westin St. Francis Hotel, San Francisco
HilleVax Participant:	Robert Hershberg, M.D., Ph.D., Chairman and Chief Executive Officer
Webcast & Audio Visual:	https://jpmorgan.metameetings.net/events/healthcare23/sessions/43891-hillevax/webcast?gpu_only=true&kiosk=true

About HilleVax

HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a VLP based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Globally, norovirus is estimated to result in over approximately 700 million cases of AGE and 200,000 deaths per year, resulting in over $4 billion in direct health system costs and $60 billion in societal costs per year. The burden of norovirus falls disproportionately on young children and older adults. For more information about HilleVax, visit the company’s website at http://www.HilleVax.com.

Contact:

Shane Maltbie
IR@hillevax.com
+1-617-213-5054